Cardio Diagnostics Holdings, Inc. reported third-quarter 2026 revenue of $3,590, compared with $2,855 a year earlier, while net loss was $1,732,331 versus $1,714,536. For the nine months, revenue was $11,630 versus $11,270 and net loss was $5,021,957 versus $5,032,799.
Cash was $3,942,882 at September 30, 2026, and operating activities used $4,420,474 in cash in the first nine months. The company said existing funds and its ATM offering are expected to fund activities over the next 12 months; it expects to need additional equity and/or debt to fund operations beyond that period. As of November 6, 2026, it had sold 2,251,181 shares under the ATM and could sell up to $5,298,889 more through Craig-Hallum.
Cardio said its high-complexity CLIA lab began testing patient samples from all states except New York, pending that state's license. Atlas Healthcare Physicians began covering Epi+Gen CHD and PrecisionCHD in May 2026, subject to prior authorization; Cardio said it secured CMS gapfill payment rates of $854 per test for both. In India, it reported engaging physicians to educate them about PrecisionCHD.
Cardio Diagnostics Holdings, Inc. (CDIO) director Wendy J. Betts received a direct award of 3,286 stock options on September 30, 2026. The options have an exercise price of $1.90 per share and expire September 30, 2036. Her directly held option position following the award was 15,656 shares.
Cardio Diagnostics Holdings, Inc. (CDIO) director Peter K. Fung received a grant of 3,286 stock options on September 30, 2026, to acquire common stock at an exercise price of $1.90 per share. After the grant, he directly held 15,656 stock options. The options expire on September 30, 2036.
Cardio Diagnostics Holdings, Inc. director James Intrater was granted 3,286 stock options on September 30, 2026. The options relate to Common Stock, carry an exercise price of $1.90 per share, and expire on September 30, 2036. His directly held stock-option position was 16,607 options following the grant.
Cardio Diagnostics Holdings, Inc. (CDIO) director Paul Frederick Burton was granted 3,286 stock options to buy Common Stock on September 30, 2026, at an exercise price of $1.90 per share. His reported direct total following the award was 16,607 options; they expire September 30, 2036.
On September 18, 2026, Cardio Diagnostics Holdings, Inc. (CDIO) held its annual meeting of stockholders, with 1,783,220 of 2,959,469 eligible common shares present or represented by proxy, a turnout of approximately 60.25%. Stockholders elected seven directors to one-year terms under a plurality vote standard.
They also approved a proposal permitting future issuance of shares of common stock and/or convertible or exercisable securities equal to 20% or more of the common stock outstanding in one or more non-public transactions, as required by Nasdaq Marketplace Listing Rule 5635(d). In addition, stockholders ratified the appointment of Prager Metis CPA’s LLC as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cardio Diagnostics Holdings, Inc. (CDIO) reported that senior management is using a new August 2026 investor presentation to brief existing and prospective investors. The company focuses on AI- and epigenetics-based blood tests for cardiovascular disease risk stratification (Epi+Gen CHD) and diagnosis (PrecisionCHD), supported by a proprietary multi-omics engine and a growing IP portfolio across multiple jurisdictions.
The presentation highlights large estimated U.S. market opportunities for these tests, a company-owned CLIA lab intended to lower costs and increase capacity, and progress toward reimbursement, including specific CPT PLA codes, a final CMS payment rate, and initial commercial coverage. It also outlines ongoing and planned clinical, economic, and utility studies, as well as U.S. and international commercialization efforts. The investor materials are furnished under Regulation FD and are not deemed filed or incorporated by reference into Securities Act filings.
Cardio Diagnostics Holdings develops AI‑driven blood tests for cardiovascular disease. For the quarter ended June 30, 2026, it generated revenue of $5,360 and incurred a net loss of $1,501,468, or $0.51 per share, on operating expenses of $1,503,507.
For the first six months of 2026, revenue was $8,040 with a net loss of $3,289,626. Cash was $5,586,697 at June 30, 2026, and stockholders’ equity totaled $7,426,283, against total liabilities of $499,780.
The company continues to fund operations primarily through equity, including $3,693,470 of net proceeds from at‑the‑market share sales in 2026. With 2,959,469 shares outstanding, management notes ongoing operating losses, modest revenue to date, and dependence on future capital raises and broader test adoption.
Cardio Diagnostics Holdings, Inc. plans a virtual annual stockholder meeting on September 18, 2026, where holders of 2,959,469 common shares as of July 31, 2026 can vote. Stockholders will elect seven directors, approve a new share-issuance authorization, and ratify Prager Metis CPA’s LLC as auditor for 2026.
The core item is the 2026 Issuance Proposal, which would permit, in one or more non-public transactions, the future sale of up to 5.0 million shares of common stock (or equivalents) for up to $10.0 million, at discounts up to 25% below market, within three months of approval (extendable to six months with Nasdaq consent), in compliance with Nasdaq Listing Rule 5635(d). If fully used, outstanding shares could rise to about 7,959,469, an increase of approximately 169%.
The company explains this authority is intended to provide an alternative capital-raising tool alongside its existing at-the-market facility, under which it has already raised about $18.75 million and issued 2,251,181 shares. The proxy discusses potential effects of any such financing, including dilution of existing ownership, possible share-price pressure, and anti-takeover implications, and outlines the board’s governance structure, committee composition, and emerging growth company status.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.